Skip to main content
JADPRO Live 2023 Main banner
Final Program


Conference Brochure
Icon Legend
Presentation Icons
CE credit available
CE credit available
Pharmacology credit available
Pharmacology credit available
Poster session
Poster session

Full Schedule

Full Schedule

  • Saturday, November 11, 2023
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium
    TRODELVY (sacituzumab govitecan-hziy) in mTNBC and Pretreated HR+/HER2- mBC: Clinical Considerations and Patient Counseling
    Gilead

    Limited seating.
    Clinical Considerations and Patient Counseling
    Melissa Carver, MSN, APRN, AOCN
    Gilead

    Ticketed event. Limited seating.
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: A first in-class NME in 3L+ follicular lymphoma & A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma
    Genentech

    Limited seating.
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Learn more about a CAR T cell therapy for relapsed/refractory multiple myeloma (RRMM)
    Bristol Myers Squibb

    Limited seating
  • 6:30 AM – 7:45 AM ET
    Breakfast Activity/Non-CE-Accredited Satellite Symposium: Myelofibrosis and Strategies for Disease Management: Key Considerations for Patient Care
    GSK

    Limited seating.
  • 6:30 AM – 6:30 PM ET
    Registration
  • 7:00 AM – 8:00 AM ET
    Exhibit Hall Open & Continental Breakfast
  • 8:00 AM – 8:15 AM ET
    Opening Remarks & APSHO Fellow (FAPO) Recognition Presentation
  • 8:10 AM – 8:30 AM ET
    The Mary Pazdur Award Presentation
  • 8:25 AM – 9:00 AM ET
    The Annual Mary Pazdur Award Recipient Lecture
  • 9:15 AM – 10:15 AM ET
    Advances and Updates in Surgical Oncology
  • 9:15 AM – 10:15 AM ET
    New Drug Updates: Solid Tumors
  • 10:15 AM – 11:15 AM ET
    Exhibit Hall Open & Refreshment Break
  • 10:15 AM – 11:15 AM ET
    Moderated Posters: Clinical Posters, Industry Encore Posters, and APSHO Patient Perspective Posters
  • 10:15 AM – 6:15 PM ET
    Braindate
  • 10:30 AM – 11:00 AM ET
    APSHO Committee Meet & Greet: Membership Committee
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation
    The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)
    Blueprint Medicines
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation
    Understanding the role of Advanced Practice Providers in the management of Low-risk Myelodysplastic Syndromes (MDS)
    Bristol Myers Squibb
  • 10:30 AM – 11:00 AM ET
    Exhibit Hall Presentation: An Overview of Clinical Data for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in 2L HER2+ Metastatic Breast Cancer
    Daiichi-Sankyo
  • 11:15 AM – 12:15 PM ET
    Benign Hematology Limbo: How Low Is Too Low?
  • 11:15 AM – 12:15 PM ET
    Improving Outcomes for Women with Metastatic HER2-Positive Breast Cancer
  • 12:15 PM – 1:45 PM ET
    Exhibit Hall & Lunch
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: A Discussion of a Real-world Patient Case of Chronic GVHD -- Intervene at the First Signs of Initial Systemic Treatment Failure
    Incyte

    Limited seating.
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: An FDA approved treatment option for anemia in LR-MDS
    Bristol Myers Squibb

    Limited seating
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: In Practice: Combination Treatment Options with Immuno-oncology in Metastatic Non-small Cell Lung Cancer and Unresectable Hepatocellular Carcinoma
    AstraZeneca

    Limited seating.
  • 12:15 PM – 1:45 PM ET
    Lunch Activity/Non-CE-Accredited Satellite Symposium: Treatment of Adults with Certain BRAF Mutation Positive Metastatic Cancers
    Pfizer Oncology

    Limited seating.
  • 12:30 PM – 1:00 PM ET
    APSHO Committee Meet & Greet: Meet the APSHO Board of Directors
  • 1:15 PM – 1:45 PM ET
    APSHO Committee Meet & Greet: Professional Development & Leadership Committee (PD&L)
  • 1:45 PM – 2:45 PM ET
    Staying Abreast of New Biomarkers in Hematology/Oncology
  • 1:45 PM – 2:45 PM ET
    Supportive Care and Coordination of Patients Receiving Immune Effector Cell Therapies: Strategies for Advanced Practitioners
  • 2:45 PM – 3:45 PM ET
    Exhibit Hall Open & Refreshment Break
  • 3:00 PM – 3:30 PM ET
    APSHO Committee Meet & Greet: Research & Quality Improvement Committee (RQI)
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation
    Janssen invites you to learn more about a treatment option for patients diagnosed with Multiple Myeloma who are Relapsed/Refractory and have received >=4 prior lines of therapy
    Janssen Oncology part of the Pharmaceutical Companies of Johnson & Johnson
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation: Discover a treatment option for certain patients with ESR1-mutated mBC
    Stemline Therapeutics
  • 3:00 PM – 3:30 PM ET
    Exhibit Hall Presentation: Practical Management of AML with a BCL2 Inhibitor
    AbbVie, US Medical Affairs
  • 3:45 PM – 4:45 PM ET
    New Drug Updates: Investigational Therapeutics in the Pipeline
  • 3:45 PM – 4:45 PM ET
    What’s Circulating? The Future of Cancer Detection and Treatment
  • 3:45 PM – 5:00 PM ET
    AP Talk: Peer Roundtables
  • 5:00 PM – 5:45 PM ET
    Independent Certified Satellite Symposium Current and Emerging Treatment Strategies in Multiple Myeloma
  • 5:45 PM – 6:30 PM ET
    >Independent Certified Satellite Symposium The Role of APs in the Treatment of NSCLC: Facilitating Effective Multidisciplinary Patient Management Strategies